Public support in the United States for global equity in vaccine pricing.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 05 2022
27 05 2022
Historique:
received:
13
10
2021
accepted:
11
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Global vaccine prices that are tiered across countries, equitable for poorer countries, and profitable for manufacturers (TEP) can promote global vaccine equity but its implementation may require political will and public support in rich countries. A survey experiment with a demographically representative sample of US adults was conducted between April and May 2021 to investigate public support for TEP and the likelihood of collective agreement on TEP relative to alternative global vaccine pricing strategies. The experiment varied vaccine cost and provision of information about the importance of equity and profitability considerations in global vaccine pricing across eight treatment conditions. TEP of low-cost vaccines received less support than TEP of high-cost vaccines, but TEP received more public support than any alternative pricing strategy. Information about equity and profitability considerations increased support for TEP of low-cost vaccines. TEP was also the most likely pricing strategy to achieve collective agreement among participants across all treatments.
Identifiants
pubmed: 35624169
doi: 10.1038/s41598-022-13172-7
pii: 10.1038/s41598-022-13172-7
pmc: PMC9137445
doi:
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8960Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2021 Jun;27(6):935-936
pubmed: 33785911
Lancet. 2014 Sep 6;384(9946):852
pubmed: 25209481
Am J Public Health. 2015 Jul;105(7):1290-3
pubmed: 25973806
Science. 2020 Sep 11;369(6509):1309-1312
pubmed: 32883884
N Engl J Med. 2021 Jul 15;385(3):193-196
pubmed: 34265190
PLoS One. 2012;7(3):e33025
pubmed: 22412979
Lancet. 2020 May 2;395(10234):1405-1406
pubmed: 32243778
Health Aff (Millwood). 2005 May-Jun;24(3):706-17
pubmed: 15886165
Int J Health Care Finance Econ. 2003 Sep;3(3):183-205
pubmed: 14625999
PLoS One. 2016 Nov 16;11(11):e0166515
pubmed: 27851831
Soc Sci Med. 2021 Aug;282:114171
pubmed: 34175572
Lancet Infect Dis. 2005 Jan;5(1):58-63
pubmed: 15620562
Gates Open Res. 2020 Feb 4;4:16
pubmed: 32185365
Global Health. 2011 Oct 12;7:39
pubmed: 21992405
Lancet. 2014 Jun 28;383(9936):2265-7
pubmed: 24636625
Pharmacoeconomics. 2018 Dec;36(12):1395-1405
pubmed: 30062518
Am J Public Health. 2006 Sep;96(9):1554-9
pubmed: 16873743
Am J Public Health. 2014 Nov;104(11):e85-91
pubmed: 25211753
Vaccine. 2017 Jul 24;35(33):4064-4071
pubmed: 28647170
BMJ. 2021 May 28;373:n1344
pubmed: 34049897
Lancet Glob Health. 2018 Dec;6(12):e1386-e1396
pubmed: 30342925